New combo therapy aims to shrink abdominal pancreatic tumors
NCT ID NCT07030283
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 25 times
Summary
This early-phase trial tests whether adding chemotherapy directly into the abdomen (intraperitoneal paclitaxel) to standard IV chemotherapy (NALIRIFOX) is safe and effective for adults with pancreatic cancer that has spread to the lining of the belly. Ten participants will receive treatment every two weeks and be monitored for side effects, tumor response, and survival. The goal is to control the disease and possibly make surgery an option for some patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Colorado Cancer Center
RECRUITINGAurora, Colorado, 80045, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.